Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.
Pharmaceutical regulatory agencies are increasingly concerned with trace-level genotoxic impurities in drug substances, requiring manufacturers to deliver innovative approaches for their analysis and control. The need to control most genotoxic impurities in the low ppm level relative to the active pharmaceutical ingredient (API), combined with the often reactive and labile nature of genotoxic impurities, poses significant analytical challenges. Therefore, sophisticated analytical methodologies are often developed to test and control genotoxic impurities in drug substances. From a quality-by-design perspective, product quality (genotoxic impurity levels in this case) should be built into the manufacturing process. This necessitates a practical analysis and control strategy derived on the premise of in-depth process understanding. General guidance on how to develop strategies for the analysis and control of genotoxic impurities is currently lacking in the pharmaceutical industry. In this work, we demonstrate practical examples for the analytical control of five genotoxic impurities in the manufacturing process of pazopanib hydrochloride, an anticancer drug currently in Phase III clinical development, which may serve as a model for the other products in development. Through detailed process understanding, we implemented an analysis and control strategy that enables the control of the five genotoxic impurities upstream in the manufacturing process at the starting materials or intermediates rather than at the final API. This allows the control limits to be set at percent levels rather than ppm levels, thereby simplifying the analytical testing and the analytical toolkits to be used in quality control laboratories.
Chemical Development, GlaxoSmithKline Pharmaceutical Research and Development, 709 Swedeland Road, King of Prussia, PA 19406, USA.
David Q
DQ
Liu
Ted K
TK
Chen
Michael A
MA
McGuire
Alireza S
AS
Kord
D002626:Chemistry, Pharmaceutical; D002853:Chromatography, Liquid; D004340:Drug Contamination; D007191:Indazoles; D013058:Mass Spectrometry; D009153:Mutagens / Q000032:analysis*; D011743:Pyrimidines / Q000737:chemistry*; D013056:Spectrophotometry, Ultraviolet; D013449:Sulfonamides / Q000737:chemistry*
D007191:Indazoles; D009153:Mutagens; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib